Details of the Drug Reposition

General Information of This Drug (ID: DMRG1X3)

Drug Name
Pirtobrutinib   DMRG1X3
Synonyms
BTK inhibitor 16; 2101700-15-4; Pirtobrutinib [USAN]; UNII-JNA39I7ZVB; JNA39I7ZVB; LOXO-305; SCHEMBL19014257; WHO 11681; HY-131328; LY3527727; CS-0133286; (S)-5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide; 1H-Pyrazole-4-carboxamide, 5-amino-3-(4-(((5-fluoro-2-methoxybenzoyl)amino)methyl)phenyl)-1-((1S)-2,2,2-trifluoro-1-methylethyl)-
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Phase 3 [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216059.
2 ClinicalTrials.gov (NCT04666038) Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL. U.S. National Institutes of Health.